Lifecell International — Billed for full cancer panel, reported only partially diagnostic negligence

Address: Guindy

Dear Sir/Madam,

We availed oncology diagnostic services from LifeCell International Pvt Ltd in July 2025. The package included genomic profiling and PD-L1 clone testing (SP263, SP142, DAKO 22C3). However, only SP263 was reported in the final document.

Key issues:
1. Reports lacked designated doctor signature and registration across pages.
2. A confusing date “12.03.2025” was mentioned without explanation.
3. Despite multiple emails and calls, no proper justification was given.
4. The company claims CAP, NABL, and ICMR accreditations — but it's unclear whether oncology diagnostics fall under their certified scope.

This misreporting delayed a critical treatment decision for our family. Please take action against this type of diagnostic negligence.

(Disclaimer: This is my genuine personal experience, shared under consumer protection laws.)